Elise Chong, MD, discusses the rationale for conducting a 4-year analysis of tisagenlecleucel in patients with relapsed/refractory diffuse large B-cell lymphoma.
Elise Chong, MD, an associate professor of Medicine at the Hospital of the University of Pennsylvania, discusses the rationale for conducting a 4-year analysis of tisagenlecleucel (Kymriah) in patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL).
There are positive 2-year data around CD19-directed chimeric antigen receptor (CAR) T-cell therapy in relapsed/refractory DLBCL. The phase I/II ZUMA-1 trial (NCT02348216), shows the efficacy and safety of CD19-directed CAR T-cell agent axicabtagene ciloleucel (KTE-C19) in refractory aggressive non-Hodgkin lymphoma, including DLBCL. The phase II JULIET trial showed the efficacy and safety of tisagenlecleucel in patients with relapsed/refractory DLBCL. The criticism around these studies, however, is that the follow-up time was short, Chong says.
The purpose of evaluating and reporting the 4-year outcomes of patients with relapsed/refractory DLBCL is to answer existing questions about the durability of CD19-directed CAR T-cell agents and whether or not there is long-term toxicity in CAR T cells.
The analysis showed that in the 24 patients with heavily pretreated, advanced stage DLBCL, 35% continued to be progression-free at a median follow-up of 49 months. Also, in patients who had a response to therapy, 60% continued responding. The overall survival in these patients was 22 months.
Examining the Non-Hodgkin Lymphoma Treatment Paradigm
July 15th 2022In season 3, episode 6 of Targeted Talks, Yazan Samhouri, MD, discusses the exciting new agents for the treatment of non-Hodgkin lymphoma, the clinical trials that support their use, and hopes for the future of treatment.
Listen
Peers Discuss Role of Pola-R-CHP vs R-CHOP in Newly Diagnosed DLBCL
April 19th 2024During a Case-Based Roundtable® event, Haifaa Abdulhaq, MD discussed with participants whether the POLARIX trial influences their choice to use the pola-R-CHP as opposed to R-CHOP regimen for patients with newly diagnosed diffuse large B-cell lymphoma.
Read More
Challenges for Non–CAR T-Cell Treatment of Early Relapsed DLBCL
April 18th 2024During a Case-Based Roundtable® event, Elizabeth A. Brém, MD, discussed treatment approaches for a patient with early relapsed or primary refractory diffuse large B-cell lymphoma in the first article of a 2-part series.
Read More